<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151487</url>
  </required_header>
  <id_info>
    <org_study_id>102013-068</org_study_id>
    <nct_id>NCT02151487</nct_id>
  </id_info>
  <brief_title>A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block</brief_title>
  <official_title>A Comparison of Ropivacaine Alone Versus Ropivacaine With Dexamethasone or Clonidine Versus a Combination of Ropivacaine, Dexamethasone, and Clonidine for Supraclavicular Brachial Plexus Block Using Ultrasound: A Prospective, Observer-blinded, Randomized Clinical Trial to Assess the Duration of Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized, observer-blinded clinical trial is to evaluate the anesthetic and
      analgesic efficacy of adding dexamethasone and clonidine to ropivacaine in supraclavicular
      nerve block. The investigators hypothesized that addition of dexamethasone and clonidine to
      ropivacaine would prolong the duration of analgesia in supraclavicular nerve block compared
      with ropivacaine alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately, 50 patients in each groups undergoing orthopedic surgery of upper extremities
      will be randomized to be one of the three groups to receive supraclavicular nerve block with
      group 1: ropivacaine alone; group 2: ropivacaine and dexamethasone; group 3: ropivacaine and
      clonidine or group 4: ropivacaine and dexamethasone and clonidine combination.

      Patients will be identified at the day surgery unit at Parkland hospital before the procedure
      and will be approached by their physician, the primary investigator, or research personnel
      for the consent for the study. If the patient chooses and consents fully to participate, he
      or she will be randomly assigned to receive one of the previously described local anesthetics
      for supraclavicular nerve block.

      The following clinical outcome will be assessed for up to 24 hr: Duration of the block, onset
      of the block, nausea, the number of vomiting, and complications of peripheral nerve block and
      used medications will be recorded. Pain at rest and movement will be evaluated by using a
      linear 10-cm visual analog scale (VAS; 0=no pain, 10= worst imaginable pain) immediately
      before the block, 5, 10, 15 minutes and 6 hr. after the block and postoperatively immediately
      at PACU, discharge from the Day surgery Unit, and 24 hr. later at home via phone call visit.

      Sensory and motor block in the related nerve dermatomes (via pinprick test) will be assessed.
      Patient will be instructed to document at what time did hand motion (finger movement) return
      and what time normal sensation (hot/cold) return. Specific time for both events will be asked
      to patient at phone call visit 24 hr later. Overall patient satisfaction will be evaluated at
      the discharge from the day surgery and 24 hr after the block via phone visit.

      At any point in which the patient is not experiencing pain relief after having received the
      injection, they will be removed from the study and other anesthetic techniques will be
      applied to resolve their pain along with pharmacological management of their pain. Rescue
      antiemetic, which is standard of care, will be given to any patient who complains of nausea
      or vomiting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of the supraclavicular block</measure>
    <time_frame>24-hr</time_frame>
    <description>Onset of the block to at the time of analgesic requirement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative analgesia</measure>
    <time_frame>24-hr</time_frame>
    <description>Post-operative pain score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Upper Extremity Fracture</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Ropivacaine 0.5% 25 ml alone for supraclavicular block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine, dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine, clonidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 ml 0.5% ropivacaine + 100 mcg clonidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine, dexamethasone, clonidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Ropivacaine alone</description>
    <arm_group_label>Ropivacaine, dexamethasone</arm_group_label>
    <arm_group_label>Ropivacaine, clonidine</arm_group_label>
    <arm_group_label>Ropivacaine, dexamethasone, clonidine</arm_group_label>
    <other_name>Noropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine, dexamethasone</intervention_name>
    <description>Ropivacaine combination with dexamethasone</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_label>Ropivacaine, clonidine</arm_group_label>
    <arm_group_label>Ropivacaine, dexamethasone, clonidine</arm_group_label>
    <other_name>Noropin and adjuvant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine, dexamethasone, clonidine</intervention_name>
    <description>Ropivacaine combination with dexamethasone and clonidine</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_label>Ropivacaine, dexamethasone</arm_group_label>
    <arm_group_label>Ropivacaine, clonidine</arm_group_label>
    <other_name>Noropin and adjuvants</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine, clonidine</intervention_name>
    <description>Ropivacaine together with clonidine</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_label>Ropivacaine, dexamethasone</arm_group_label>
    <arm_group_label>Ropivacaine, dexamethasone, clonidine</arm_group_label>
    <other_name>Noropin and adjuvant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18-80 years old

          -  Undergoing upper extremity surgery

          -  Receiving Supraclavicular block

          -  Able to give Informed consent

        Exclusion Criteria:

          -  Age less than 18 and greater than 80 years

          -  Inability to understand the study procedures

          -  Significant respiratory dysfunction

          -  Preexisting neurologic deficits

          -  Allergy to local anesthetics

          -  A bleeding diathesis or on anticoagulants

          -  Systemic glucocorticoid use

          -  Refuse to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawood Nasir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkland Health Hospital System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>750390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Supraclavicular block</keyword>
  <keyword>Ropivacaine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Clonidine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>April 20, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

